SevenBridge Financial Group LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

SevenBridge Financial Group LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 5.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 168,967 shares of the biopharmaceutical company’s stock after purchasing an additional 7,992 shares during the quarter. SevenBridge Financial Group LLC’s holdings in Pfizer were worth $4,890,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new position in shares of Pfizer in the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $29,000. Gladius Capital Management LP boosted its holdings in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP purchased a new stake in shares of Pfizer in the second quarter valued at approximately $31,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer in the second quarter valued at approximately $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 2.1 %

Shares of NYSE PFE opened at $25.65 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $145.36 billion, a PE ratio of 34.66, a PEG ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a fifty day simple moving average of $28.21 and a 200-day simple moving average of $28.57.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insiders Place Their Bets

In related news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PFE. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. Finally, UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.